Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Polymorphisms in microRNA binding sites of mucin genes as predictors of clinical outcome in colorectal cancer patients

V. Vymetalkova, B. Pardini, F. Rosa, K. Jiraskova, C. Di Gaetano, P. Bendova, M. Levy, V. Veskrnova, T. Buchler, L. Vodickova, A. Naccarati, P. Vodicka,

. 2017 ; 38 (1) : 28-39. [pub] 20161101

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031315

Grantová podpora
NT13424 MZ0 CEP - Centrální evidence projektů

Polymorphisms in microRNA (miRNA) binding sites may affect miRNA/target gene interaction, resulting in differential mRNA/protein expression and susceptibility to common diseases. Mucins have been identified as markers of adverse prognosis. We hypothesized that genetic variations in miRNA binding sites located in mucin genes may modulate signaling response and the maintenance of genomic stability ultimately affecting cancer susceptibility, efficacy of chemotherapy and survival. In this study, we analyzed the association of single nucleotide polymorphisms in predicted miRNA target sites (miRSNPs) of mucin genes with colorectal cancer (CRC) risk and clinical outcome. Thirteen miRSNPs in 9 genes were assessed in 1111 cases and 1469 controls. No strongly significant associations were observed in the case-control study. Patients carrying the CC genotype of rs886403 in MUC21 displayed a shorter survival and higher recurrence risk when compared with TT carriers [overall survival (OS): hazard ratios (HR) 1.69; 95% confidence intervals (CI) 1.13-2.46; P = 0.01 and event-free survival (EFS): HR 1.99; 95% CI 1.38-2.84; P = 0.0002, respectively]. The observed associations were more striking after stratification for tumor site (in patients with colon cancer, OS: HR 2.63; 95% CI 1.69-4.10; P < 0.0001 and EFS: HR 2.65; 95% CI 1.72-4.07; P < 0.0001). In contrast, rectal cancer cases carrying the CC genotype of rs4729655 in MUC17 displayed a longer survival (OS: HR 0.27; 95% CI 0.14-0.54; P = 0.0002) than those with the most common genotype. To our knowledge, this is the first study investigating miRSNPs potentially affecting miRNA binding to mucin genes and revealing their impact on CRC susceptibility or patient's survival.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031315
003      
CZ-PrNML
005      
20181113110105.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/carcin/bgw114 $2 doi
035    __
$a (PubMed)27803053
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vymetálková, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, 14200 Prague, Czech Republic, vpolakova@biomed.cas.cz. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 11000 Prague, Czech Republic. $7 xx0102721
245    10
$a Polymorphisms in microRNA binding sites of mucin genes as predictors of clinical outcome in colorectal cancer patients / $c V. Vymetalkova, B. Pardini, F. Rosa, K. Jiraskova, C. Di Gaetano, P. Bendova, M. Levy, V. Veskrnova, T. Buchler, L. Vodickova, A. Naccarati, P. Vodicka,
520    9_
$a Polymorphisms in microRNA (miRNA) binding sites may affect miRNA/target gene interaction, resulting in differential mRNA/protein expression and susceptibility to common diseases. Mucins have been identified as markers of adverse prognosis. We hypothesized that genetic variations in miRNA binding sites located in mucin genes may modulate signaling response and the maintenance of genomic stability ultimately affecting cancer susceptibility, efficacy of chemotherapy and survival. In this study, we analyzed the association of single nucleotide polymorphisms in predicted miRNA target sites (miRSNPs) of mucin genes with colorectal cancer (CRC) risk and clinical outcome. Thirteen miRSNPs in 9 genes were assessed in 1111 cases and 1469 controls. No strongly significant associations were observed in the case-control study. Patients carrying the CC genotype of rs886403 in MUC21 displayed a shorter survival and higher recurrence risk when compared with TT carriers [overall survival (OS): hazard ratios (HR) 1.69; 95% confidence intervals (CI) 1.13-2.46; P = 0.01 and event-free survival (EFS): HR 1.99; 95% CI 1.38-2.84; P = 0.0002, respectively]. The observed associations were more striking after stratification for tumor site (in patients with colon cancer, OS: HR 2.63; 95% CI 1.69-4.10; P < 0.0001 and EFS: HR 2.65; 95% CI 1.72-4.07; P < 0.0001). In contrast, rectal cancer cases carrying the CC genotype of rs4729655 in MUC17 displayed a longer survival (OS: HR 0.27; 95% CI 0.14-0.54; P = 0.0002) than those with the most common genotype. To our knowledge, this is the first study investigating miRSNPs potentially affecting miRNA binding to mucin genes and revealing their impact on CRC susceptibility or patient's survival.
650    _2
$a 3' nepřekládaná oblast $x genetika $7 D020413
650    _2
$a senioři $7 D000368
650    _2
$a vazebná místa $7 D001665
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kolorektální nádory $x genetika $x mortalita $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a muciny $x genetika $x metabolismus $7 D009077
650    _2
$a lokální recidiva nádoru $x genetika $x mortalita $x patologie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a prognóza $7 D011379
650    _2
$a míra přežití $7 D015996
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pardini, Barbara $u Human Genetics Foundation, 10126 Turin, Italy. $7 _AN058834
700    1_
$a Rosa, Fabio $u Human Genetics Foundation, 10126 Turin, Italy.
700    1_
$a Jiraskova, Katerina $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, 14200 Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 11000 Prague, Czech Republic.
700    1_
$a Di Gaetano, Cornelia $u Human Genetics Foundation, 10126 Turin, Italy. Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
700    1_
$a Bendova, Petra $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, 14200 Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 11000 Prague, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic.
700    1_
$a Levý, Miroslav $u Department of Surgery, First Faculty of Medicine, Charles University and Thomayer University Hospital, 14200 Prague, Czech Republic and. $7 xx0198664
700    1_
$a Veskrnova, Veronika $u Department of Oncology, Thomayer Hospital and First Faculty of Medicine, Charles University, 11000 Prague, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, Thomayer Hospital and First Faculty of Medicine, Charles University, 11000 Prague, Czech Republic.
700    1_
$a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, 14200 Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 11000 Prague, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic.
700    1_
$a Naccarati, Alessio $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, 14200 Prague, Czech Republic. Human Genetics Foundation, 10126 Turin, Italy.
700    1_
$a Vodička, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, 14200 Prague, Czech Republic. Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 11000 Prague, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic. $7 xx0060269
773    0_
$w MED00001050 $t Carcinogenesis $x 1460-2180 $g Roč. 38, č. 1 (2017), s. 28-39
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27803053 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20181113110150 $b ABA008
999    __
$a ok $b bmc $g 1254908 $s 992342
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 38 $c 1 $d 28-39 $e 20161101 $i 1460-2180 $m Carcinogenesis $n Carcinogenesis $x MED00001050
GRA    __
$a NT13424 $p MZ0
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace